Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage - Wikidata - awgldk - TriplyDB

Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage

Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage

http://www.wikidata.org/entity/Q28547661

about

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future Theranostic Role of 32P-ATP as Radiopharmaceutical for the Induction of Massive Cell Death within Avascular Tumor Core.Impact of Methods on the Measurement of mRNA Turnover.

P2860

Q41487973-83EDB033-82BC-4834-A7C6-D75E5705F57D Q47160527-30B7DFD7-CE0A-4F73-84F8-1998E06F7080 Q47171522-D60601F3-0070-40D8-BD24-698F297F0AC2

P2860

Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage

http://www.wikidata.org/entity/Q28547661

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@ast

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@en

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@nl

type

label

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@ast

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@en

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@nl

prefLabel

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@ast

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@en

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@nl

P1433

Q28547661-97B0F10C-C787-4AAD-80FE-1B7C36D39251

P1476

Q28547661-B4034A9F-EBC3-4E68-B12D-875E7D5EE4AB

P2093

Q28547661-40927F6D-9116-47DC-A4E7-96EB11C82735

Q28547661-6F131254-A696-4B4D-B7AB-DF572E0A66C0

Q28547661-729A5D55-8669-4C39-B3E6-D203A0FF49D5

Q28547661-9051E78B-BC1D-46ED-8610-52A73F18E1CF

Q28547661-D6D2202D-0AD9-461C-B82E-C1196F2D0F1B

Q28547661-E8173937-9F9D-40A9-9C63-997F7EDC1B66

P2860

Q28547661-18167F12-22AA-4A29-ADC7-18D462126C09

Q28547661-18F1C991-4948-404D-9166-A781C82D6F2C

Q28547661-26B823C2-F17D-4185-ABE2-4CCE0AE7B1D5

Q28547661-3524A638-88A9-4856-B6F9-78B10FFF8478

Q28547661-35C4E09D-CDED-4B5B-BDD9-54C686FEBC63

Q28547661-37C66EE2-ECE7-4D30-ABFB-53F12D121AE7

Q28547661-5EEA2848-D8F5-46AA-8192-4ECD857D5B85

Q28547661-6A2512DE-653E-4C0E-B611-BBF982FA1AB3

Q28547661-704E27D5-E463-4A1A-825D-C17FC04A132F

Q28547661-787F18BE-B640-4D5C-9D8C-845683BC77CB

P304

Q28547661-C668A49A-D3DB-4100-88DC-DA713244C1E0

P31

Q28547661-2FBED24C-1FE2-477C-B042-624D19DFAD3C

P356

Q28547661-1DE812FC-36A4-45CF-B841-9AF110684219

P407

Q28547661-9DF809DC-46BB-48BD-BA78-80AE00EC15B8

P433

Q28547661-827963E9-B686-41E7-B74F-BB7CB5EBCC1B

P478

Q28547661-8ABE76D7-3183-44AE-B61A-6CC875D06737

P577

Q28547661-320BA1FB-2958-400F-9DC1-5E3F6BD7B1B6

P5875

Q28547661-B94C10EA-9CF4-431E-868A-54A583AA883D

P698

Q28547661-51456843-9D02-4B67-9A38-2A269174981C

P932

Q28547661-4187086E-5974-4C93-9031-9714643C7E2B

P356

JOURNAL.PONE.0128152

P1433

P1476

Phosphorus-32, a clinically av ...... ing DNA double-strand breakage

@en

P2093

Ana P Kiess

http://www.w3.org/2001/XMLSchema#string

John M Abraham

http://www.w3.org/2001/XMLSchema#string

Joseph M Herman

http://www.w3.org/2001/XMLSchema#string

Martin G Pomper

http://www.w3.org/2001/XMLSchema#string

Stephen J Meltzer

http://www.w3.org/2001/XMLSchema#string

Yulan Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Mouse xenograft models vs GEM models for human cancer therapeutics

Buffer gradient gels and 35S label as an aid to rapid DNA sequence determination

Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX

DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1

Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer

Teletherapy and radiopharmaceutical therapy of painful bone metastases.

Establishment of human tumor xenografts in immunodeficient mice.

EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.

Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.

In vivo molecular targeted radiotherapy.

P304

e0128152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0128152

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277902504

http://www.w3.org/2001/XMLSchema#string

P698

26030880

http://www.w3.org/2001/XMLSchema#string

P932

4450878

http://www.w3.org/2001/XMLSchema#string